Pancreatic Cancer Research

ResearcherUniversity of California, Los AngelesActive in the last 2 years

Hiroki Takahashi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0528-0446; OpenAlex author ID A5023093481. Sources: OpenAlex.

Their work

Papers
18
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper

Papers 18

  1. The Natural Compound CalebinA Suppresses Gemcitabine Resistance and Tumor Progression by Inhibiting Angiogenesis and Invasion Through NF-κB Signaling in Pancre… Co-author DOI 10.3390/nu17162641↗
  2. Expression of ZKSCAN3 protein suppresses proliferation, migration, and invasion of pancreatic cancer through autophagy. Co-author DOI 10.1111/cas.16173↗
  3. The Natural Product Parthenolide Inhibits Both Angiogenesis and Invasiveness and Improves Gemcitabine Resistance by Suppressing Nuclear Factor κB Activation in… Co-author DOI 10.3390/nu16050705↗
  4. Upregulation of integrin‑linked kinase enhances tumor progression in gemcitabine‑resistant pancreatic cancer. Co-author DOI 10.3892/or.2023.8601↗
  5. Girdin regulates both migration and angiogenesis in pancreatic cancer cell lines. Co-author DOI 10.3892/or.2023.8606↗
  6. 10Z‑Hymenialdisine inhibits angiogenesis by suppressing NF‑κB activation in pancreatic cancer cell lines. Co-author DOI 10.3892/or.2022.8259↗
  7. Enhanced CXCL12/CXCR4 signaling increases tumor progression in radiation‑resistant pancreatic cancer. Co-author DOI 10.3892/or.2022.8279↗
  8. Escin inhibits angiogenesis by suppressing interleukin‑8 and vascular endothelial growth factor production by blocking nuclear factor‑κB activation in pancreat… Co-author DOI 10.3892/or.2021.8006↗
  9. Acquisition of gemcitabine resistance enhances angiogenesis via upregulation of IL‑8 production in pancreatic cancer. Co-author DOI 10.3892/or.2019.7105↗
  10. [A Case of Conversion Surgery for an Initially Locally Advanced Unresectable Pancreatic Cancer after S-1 Chemotherapy]. Co-author PMID 32156996↗
  11. Xanthohumol inhibits angiogenesis by suppressing nuclear factor-κB activation in pancreatic cancer. Co-author DOI 10.1111/cas.13441↗
  12. Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists. Co-author DOI 10.1186/s12885-016-2340-z↗
  13. Zerumbone inhibits angiogenesis by blocking NF-κB activity in pancreatic cancer. Co-author DOI 10.1097/mpa.0000000000000039↗
  14. Simultaneous knock-down of Bcl-xL and Mcl-1 induces apoptosis through Bax activation in pancreatic cancer cells. Co-author DOI 10.1016/j.bbamcr.2013.08.006↗
  15. Evidence for activation of mutated p53 by apigenin in human pancreatic cancer. Co-author DOI 10.1016/j.bbamcr.2011.12.008↗
  16. Apigenin inhibits NNK-induced focal adhesion kinase activation in pancreatic cancer cells. Co-author DOI 10.1097/mpa.0b013e31824d64d9↗
  17. Baicalein, a component of Scutellaria baicalensis, induces apoptosis by Mcl-1 down-regulation in human pancreatic cancer cells. Co-author DOI 10.1016/j.bbamcr.2011.05.003↗
  18. Cyclooxygenase-2 confers growth advantage to syngeneic pancreatic cancer cells. Co-author DOI 10.1097/mpa.0b013e31820b9733↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yoichi Matsuo · 14 shared papers, 2013–2025 · strength 1.63
  2. Kenta Saito · 12 shared papers, 2016–2025 · strength 1.55
  3. Shuji Takiguchi · 11 shared papers, 2018–2025 · strength 1.49
  4. Mamoru Morimoto · 11 shared papers, 2016–2024 · strength 1.34
  5. Hiroyuki Imafuji · 10 shared papers, 2018–2024 · strength 1.29
  6. Tomokatsu Kato · 8 shared papers, 2021–2025 · strength 1.25
  7. Hiromichi Murase · 7 shared papers, 2022–2025 · strength 1.13
  8. Keisuke Nonoyama · 5 shared papers, 2023–2025 · strength 0.87
  9. Yuki Denda · 5 shared papers, 2023–2025 · strength 0.87
  10. Yuichi Hayashi · 7 shared papers, 2019–2023 · strength 0.85
  11. Kan Omi · 6 shared papers, 2019–2023 · strength 0.70
  12. Goro Ueda · 6 shared papers, 2019–2023 · strength 0.70
  13. Saburo Sugita · 3 shared papers, 2024–2025 · strength 0.57
  14. Yuki Eguchi · 3 shared papers, 2024–2025 · strength 0.57
  15. Tomoya Shamoto · 3 shared papers, 2014–2018 · strength 0.18
  16. Howard A. Reber · 5 shared papers, 2011–2013 · strength 0.15
  17. Guido Eibl · 5 shared papers, 2011–2013 · strength 0.15
  18. Oscar Joe Hines · 5 shared papers, 2011–2013 · strength 0.15
  19. Hiromitsu Takeyama · 3 shared papers, 2013–2016 · strength 0.14
  20. Hung Pham · 3 shared papers, 2011–2013 · strength 0.09
  21. Jonathan C. King · 3 shared papers, 2011–2012 · strength 0.08
  22. Vay Liang W. Go · 2 shared papers, 2011–2012 · strength 0.05
  23. Stephen Jacob Pandol · 1 shared paper, 2012 · strength 0.03
  24. David W. Dawson · 1 shared paper, 2011 · strength 0.03
  25. Qing‐Yi Lu · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.